Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Experimental Hematology|September 20, 2006
Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantationMiquel Granell, Alvaro Urbano-Ispizua, Belén Suarez, et al.
Blood|December 7, 2007
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A Brodsky, Neal S Young, Elisabetta Antonioli, et al.
Blood|September 6, 2008
Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantationMiquel Granell, Alvaro Urbano-Ispizua, Aina Pons, et al.
British Journal of Haematology|February 16, 2010
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumabRichard Kelly, Louise Arnold, Stephen Richards, et al.
European Journal of Haematology|December 10, 2020
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumabAustin G Kulasekararaj, Anita Hill, Saskia Langemeijer, et al.
Blood|December 5, 2018
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 studyAustin G Kulasekararaj, Anita Hill, Scott T Rottinghaus, et al.
Annals of Hematology|July 28, 2017
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH RegistryAna Villegas, Ramiro Núñez, Anna Gaya, et al.
Plos One|September 4, 2020
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuriaJohn Devin Peipert, Austin G Kulasekararaj, Anna Gaya, et al.
Hematology (Amsterdam, Netherlands)|June 11, 2026
Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapiesCarlos Vallejo, Carmen González, Anna Gaya, et al.
American Journal of Hematology|June 17, 2024
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitionAlexander Röth, Guangsheng He, Hongyan Tong, et al.
Pageof 4